Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.66 |
| ▸ | GUSB | P08236 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250496 | 0.91 | DGAT1 (0.80) | DGAT1GUSBCHEK2EGFRERBB2 | |
| SCHEMBL1252168 | 0.87 | DGAT1 (0.59) | DGAT1GUSBCHEK2EGFRERBB2 | |
| SCHEMBL1252108 | 0.84 | DGAT1 (0.65) | DGAT1GUSBCHEK2EGFRERBB2 | |
| SCHEMBL10299677 | 0.83 | DGAT1 (0.83) | DGAT1GUSBCHEK2 | |
| SCHEMBL1252088 | 0.80 | DGAT1 (1.00) | DGAT1GUSBEGFRERBB2 | |
| SCHEMBL30385183 | 0.80 | DGAT1 (1.00) | DGAT1GUSBEGFRERBB2 | |
| SCHEMBL1252216 | 0.80 | DGAT1 (1.00) | DGAT1GUSBCHEK2 | |
| SCHEMBL30385298 | 0.80 | DGAT1 (1.00) | DGAT1GUSBCHEK2 | |
| SCHEMBL1252711 | 0.79 | DGAT1 (0.80) | DGAT1GUSBEGFRERBB2 | |
| SCHEMBL30385827 | 0.79 | DGAT1 (0.80) | DGAT1GUSBEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | claimed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | claimed |
| WO-2011123401-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | claimed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | claimed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | claimed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | claimed |
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9061012-B2 | Uses of DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013169648-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DGAT1 INHIBTOR AND A TRIGLYCERIDE LOWERING DRUG | NOVARTIS AG (CH) | 2013-11-14 | — | — | WO | disclosed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885GUSB 945/4885CHEK2 4495/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885CHEK2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.